Comparison
6q Terminal Deletion Syndrome C4304514 vs 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Clinical comparison between 6Q Terminal Deletion Syndrome and 3 Beta Hydroxysteroid Dehydrogenase Deficiency for differential diagnosis and treatment planning.
6q Terminal Deletion Syndrome C4304514
A chromosomal disorder involving deletion of genetic material at the end of chromosome 6, leading to developmental delays and variable physical features.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
A rare genetic disorder affecting adrenal hormone production. It can cause ambiguous genitalia, salt-wasting crises, and hormonal imbalances. Treatment requires hormone replacement therapy and careful monitoring.
6 comparison axes
Onset
6q Terminal Deletion Syndrome C4304514
0-0
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
0-null
Onset patterns differ
Severity
6q Terminal Deletion Syndrome C4304514
severe
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
severe
Different severity levels
Chronic
6q Terminal Deletion Syndrome C4304514
Chronic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Chronic
Differing course
Communicable
6q Terminal Deletion Syndrome C4304514
No
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
No
Different transmission
Body System
6q Terminal Deletion Syndrome C4304514
congenital
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
Same/different system
Category
6q Terminal Deletion Syndrome C4304514
genetic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
Different category
Bottom line
6q-terminal-deletion-syndrome-C4304514 and 3-beta-hydroxysteroid-dehydrogenase-deficiency-C0342471 differ in etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 6q Terminal Deletion Syndrome C4304514 | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | Discriminating power |
|---|---|---|---|
| Developmental delay | Often a core feature with variable intellectual disability. | Not the defining feature; neurologic effects are not established here. | Moderate |
| Genital appearance | Physical anomalies may occur but are variable and not specific. | Ambiguous genitalia can occur from disordered sex-steroid production. | Moderate |
| Salt-wasting crisis | Not characteristic of the chromosomal deletion itself. | May present with adrenal insufficiency and salt loss; severity varies. | High |
When to favor each condition
Choose 6q Terminal Deletion Syndrome C4304514 when
Congenital developmental delay with dysmorphic features
A chromosomal microarray or karyotype can assess terminal 6q deletion.
High
Family or prenatal concern for a structural chromosome change
Genetic testing targets the deletion rather than steroid enzymes.
Moderate
No biochemical evidence of adrenal steroid-pathway failure
Absence of that pattern makes the endocrine diagnosis less likely.
Low
Choose 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 when
Infant with suspected adrenal crisis or salt loss
Urgent endocrine evaluation is appropriate; exact thresholds are not supplied.
High
Ambiguous genitalia with suspected steroid-synthesis disorder
Hormone profiling and HSD3B2-related testing may be considered.
Moderate
Need for long-term hormone replacement planning
Management centers on endocrine replacement and monitoring, not chromosomal care alone.
Moderate
How key tests differ
| Test | 6q Terminal Deletion Syndrome C4304514 | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | Interpretation |
|---|---|---|---|
| Chromosomal microarray or karyotype | May identify deletion of terminal 6q material. | Not expected to diagnose the enzyme deficiency. | A positive deletion supports the left condition; clinical correlation remains necessary. |
| Adrenal steroid profile | No characteristic steroid pattern is established. | May show disordered precursor and product ratios; cutoffs are not provided. | Abnormal results suggest, but do not alone prove, the enzyme deficiency. |
| Gene or enzyme-pathway testing | Focus is chromosomal rather than HSD3B2. | HSD3B2 or related testing may support the diagnosis. | Test choice should follow the suspected mechanism and specialist review. |
Prognosis comparison
6q Terminal Deletion Syndrome C4304514
- Outcome
- Chronic course with variable developmental and physical effects; exact prognosis is not established.
- Factors
- Deletion extent, associated anomalies, and developmental support may influence outcome.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
- Outcome
- Chronic endocrine disorder; outcome depends on recognition and hormone management.
- Factors
- Salt-wasting severity, hormone imbalance, and monitoring adherence are relevant.
Time frame: Both may be lifelong; onset data are limited and should not be overinterpreted.
No mortality or prevalence figures are supplied, so prognosis must be individualized.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal insufficiency | Not an established direct complication. Can cause life-threatening salt-wasting or cortisol deficiency. Emergency care is needed for suspected crisis; doses are not specified here. |
| Developmental disability | Variable developmental delay is expected. Not the primary described complication. Support needs depend on individual assessment. |
| Genital and reproductive effects | Variable congenital anomalies may occur. Ambiguous genitalia and hormonal imbalance are described. Specialist counseling is required; outcomes are not uniform. |
Patient education highlights
- HighDifferent causes
One is a chromosome deletion; the other impairs adrenal hormone production. Neither is communicable.
- HighUrgent warning signs
Poor feeding, vomiting, dehydration, or collapse in the endocrine disorder needs urgent care.
- MediumIndividual variability
Features and support needs vary. A clinician should interpret tests and guide monitoring.